INmune Bio, Inc. (INMB) vs Rani Therapeutics Holdings, Inc. (RANI)
A side-by-side comparison of INmune Bio, Inc. and Rani Therapeutics Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INMB
INmune Bio, Inc.
$1.90HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
RANI
Rani Therapeutics Holdings, Inc.
$0.79HealthcareDelayed quote: Oct 6, 2026, 12:23 PM EDT
Total return — INMB vs RANI
growth of $100 · dividends reinvested · last 5yINMB -87.7% (-34.3%/yr)RANI -93.0% (-41.2%/yr)INMB compounded faster over this window
INMB RANI
INMB vs RANI: by the numbers
- •RANI is the larger company ($51M vs $51M market cap).
- •Both run net losses; RANI's is the smaller (-618.02% vs -91866.00% net margin).
Metrics side by side
Valuation
| Metric | INMB | RANI |
|---|---|---|
| P/S ratio | N/A | 10.52 |
| P/B ratio | 2.48 | 1.31 |
Profitability
| Metric | INMB | RANI |
|---|---|---|
| Gross margin | 100.00% | 44.89% |
| Operating margin | -61738.00% | -2345.99% |
| Net margin | -91866.00% | -618.02% |
| ROE | -90.44% | -76.82% |
| ROIC | -96.37% | -63.96% |
Growth (annualized)
| Metric | INMB | RANI |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 9.95% |
| Total return CAGR (5Y) | -36.88% | -46.70% |
Frequently asked
- How have INMB and RANI total returns compared?
- Over the past 5 years, INMB delivered -36.88% and RANI delivered -46.70% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.